Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.63 |
| ▸ | EGFR | P00533 | 7/20 | 0.63 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12461974 | 0.89 | MAPK14 (0.63) | MAPK14EGFRIKBKBCHUKDAPK3 | |
| SCHEMBL12461973 | 0.89 | MAPK14 (0.71) | MAPK14EGFRIKBKBCHUKDAPK3 | |
| SCHEMBL12461971 | 0.88 | MAPK14 (0.67) | MAPK14EGFRIKBKBCHUKDAPK3 | |
| SCHEMBL12462000 | 0.86 | MAPK14 (0.59) | MAPK14EGFRNUDT1MAPK13RAF1 | |
| SCHEMBL12461918 | 0.84 | BRAF (0.48) | MAPK14EGFRRAF1 | |
| SCHEMBL12461966 | 0.84 | MAPK14 (0.64) | MAPK14EGFRMAPK13RAF1MAPK12 | |
| SCHEMBL12461976 | 0.84 | MAPK14 (0.64) | MAPK14EGFRIKBKBCHUKDAPK3 | |
| SCHEMBL12461972 | 0.82 | MAPK14 (0.70) | MAPK14EGFRIKBKBCHUKDAPK3 | |
| SCHEMBL12461975 | 0.82 | MAPK14 (0.59) | MAPK14EGFRIKBKBCHUKDAPK3 | |
| SCHEMBL12461987 | 0.81 | MAPK14 (0.66) | MAPK14EGFRIKBKBCHUKDAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 193/4885EGFR 232/4885NUDT1 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.